You take the recommended dose, wait the recommended amount of time, and the pain barely dulls. Meanwhile someone else takes the same pill for the same kind of pain and feels real relief. This isn’t about pain tolerance or exaggeration — it often comes down to biology, including how your body activates or processes the drug itself, and genetics like CYP2D6 variation plays a documented role here alongside factors like the type and severity of pain, other medications, and general health. Codeine, for instance, has to be converted by the CYP2D6 enzyme into morphine to work, and people who metabolize poorly through this pathway get little to no pain relief from it at any dose (CPIC Codeine Guideline). This is educational information, not a substitute for talking to your doctor about pain management.
CYP2D6 and Opioids That Need Activation First
Several common opioid painkillers, including codeine and tramadol, are what’s called prodrugs — they don’t work directly, but need to be converted by an enzyme into an active form first. CYP2D6 does most of that converting.
When the Painkiller Simply Doesn’t Activate
People classified as CYP2D6 poor metabolizers, roughly 5 to 10% of people of European descent and smaller percentages of other ancestries, convert very little codeine into morphine, leaving them with minimal pain relief no matter the dose (CPIC-based summary). Tramadol works the same way and tends to fail for the same reason. Clinical guidelines from CPIC now recommend that poor metabolizers avoid both drugs altogether in favor of an alternative that doesn’t depend on CYP2D6 for activation, such as morphine itself (CPIC Codeine Guideline).
Real-World Evidence That Genetics-Guided Prescribing Helps
This isn’t just theoretical. A pragmatic clinical trial that used CYP2D6 genetic testing to guide opioid prescribing found that intermediate and poor metabolizers who received genetics-guided care had significantly greater improvement in pain control compared to those receiving usual care, while normal metabolizers showed no difference between the two approaches — exactly what you’d expect if the genetic information were adding real value specifically for the group whose metabolism actually diverges from typical (Smith et al., 2019).
OPRM1 and How Tightly Your Receptors Bind Opioids
Whether an opioid gets activated is only half the story. Once it’s in your system, it has to bind to opioid receptors to produce relief, and a common variant in the OPRM1 gene changes how well that binding happens. Carriers of the variant G allele (A118G) have opioid receptors with an altered ability to bind natural and drug-derived opioids, and this variant has been associated with differences in pain threshold across several studies (Holliday & McBeth, 2011). In practical terms, this is one reason two people can receive comparable blood levels of an opioid and still report very different amounts of relief.
GCH1 and the “Pain-Protective” Haplotype
Not every pain-related gene is about drug metabolism — some affect how sensitive your nervous system is to begin with. GCH1 codes for an enzyme involved in producing a compound that helps regulate pain-signaling nerve fibers. In 2006, researchers identified a specific combination of variants, now called the “pain-protective” haplotype, that was associated with reduced pain sensitivity after mechanical stimulation and lower pain following spinal surgery in the original discovery study.
Since then, the picture has gotten more complicated, which is worth stating plainly. Some follow-up studies confirmed the protective effect on pain sensitivity, while others found no association at all, including studies on pain after dental surgery, in people with pancreatitis, and in women with a chronic vestibular pain condition (Holliday & McBeth, 2011). A separate study on labor pain found that carriers of the haplotype didn’t show a meaningful difference in how they experienced or managed pain during delivery (Dabo et al., 2010). GCH1 remains a legitimate and actively studied piece of the pain-genetics puzzle, but it’s clearly not a universal predictor across every type of pain.
Non-Genetic Reasons Painkillers Underperform
Chronic use of any painkiller can lead to tolerance, meaning the same dose becomes less effective over time regardless of genetics. Poor sleep, unmanaged stress, and untreated depression are all known to amplify pain perception. Certain other medications can also inhibit or compete for the same metabolic enzymes, effectively changing how a painkiller behaves in your body even if your genetics haven’t changed at all. If a medication isn’t controlling your pain, that’s worth bringing directly to your doctor rather than adjusting the dose yourself.
Where Genetic Testing Fits In
If you’ve ever wondered whether biology explains why a painkiller didn’t work as expected, a medication check pharmacogenomic report can walk through markers like these in personalized detail. It’s meant to support a conversation with your doctor about pain management options, not to guide dosing decisions on your own.
Frequently Asked Questions
Why doesn’t codeine work for some people at all?
Codeine needs to be converted into morphine by the CYP2D6 enzyme to relieve pain. People who are CYP2D6 poor metabolizers convert very little of it, so they get minimal relief regardless of dose.
Should I take more painkiller if the standard dose isn’t working?
No. Increasing a dose on your own can be dangerous, especially with combination products containing acetaminophen. Talk to your doctor about alternative options instead.
Is there a single gene that predicts pain tolerance?
No single gene fully explains pain tolerance. Genes like GCH1, OPRM1, and CYP2D6 each contribute modestly to different aspects of pain sensitivity or drug response, and non-genetic factors play a substantial role too.
